| Budget Amount *help |
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2017: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2016: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2015: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
|
|---|
| Outline of Final Research Achievements |
To elucidate the comprehensive influence on pancreatic cancer tissue and various type of immune cells infiltrating tumor microenvironment to tumor-specific immune system, we analyzed the expression of various tumor immunity-related molecules in pancreatic cancer tissue and peripheral blood sample which were obtained from patients with pancreatic cancer undergoing clinical trials of dendritic cell-based immunotherapy.
As a result, it was revealed that there is a significantly high correlation between infiltration of CD163 positive M2 macrophages and CD66b positive granulocytes in cancer microenvironment with poor prognosis and CD20 positive B cell infiltration as good prognosis. Peripheral blood neutrophil / lymphocyte ratio and serum IL-6 level were also poor prognostic markers. The discovery of this prognosis-associated biomarker may lead to the development of a new composite cancer immunotherapy.
|
